We read with interest the comments by Dr Piccaluga et al 1, 2 regarding our report on the use of alemtuzumab in an adult patient with refractory acute lymphocytic leukemia (ALL), who has now remained in complete remission for 20 months and remains so at the time of writing, albeit still without complete recovery of normal blood counts, as initially reported. 3 We have extended our experience on three additional patients with refractory ALL. In the first one, we observed no response; we checked for the presence of the CD52 antigen at the surface of blast cells and found that it was absent and not covered by the CD52 antibody administered, using a human anti-IGG globulin. A second patient had a CD52-positive refractory ALL3 with very high tumor load: we observed a reduction in testicular leukemic infiltration and a weak and transient decrease in peripheral blood blast cell counts, but the marrow aspirate remained infiltrated. The third patient had a hypercellular Ph1-positive ALL diagnosed in December 2003. He was treated by hyper C-VAD and imatinib. He reached complete cytological and chromosomal remission in March 2004, but within 6 weeks, Ph1-positive cells had reappeared and the molecular quantification of the b2a3 transcript was very high. Mab Campath was introduced and imatinib pursued. After six infusions of alemtuzumab, in May 2004, we observed a disappearance of Ph1-positive cells in the marrow and a profound decrease in b2a3 quantification. Unfortunately, we discontinued Mab Campath because of severe neurologic toxicity (peripheral neuropathy and myelitis) of unknown origin since we could not rule out its responsibility. It should be mentioned that in July 2004, Avivi et al 4 reported for the first time similar neurological complications following alemtuzumab-based reduced intensity allogeneic transplantation.
TO THE EDITOR
We read with interest the comments by Dr Piccaluga et al 1, 2 regarding our report on the use of alemtuzumab in an adult patient with refractory acute lymphocytic leukemia (ALL), who has now remained in complete remission for 20 months and remains so at the time of writing, albeit still without complete recovery of normal blood counts, as initially reported. 3 We have extended our experience on three additional patients with refractory ALL. In the first one, we observed no response; we checked for the presence of the CD52 antigen at the surface of blast cells and found that it was absent and not covered by the CD52 antibody administered, using a human anti-IGG globulin. A second patient had a CD52-positive refractory ALL3 with very high tumor load: we observed a reduction in testicular leukemic infiltration and a weak and transient decrease in peripheral blood blast cell counts, but the marrow aspirate remained infiltrated. The third patient had a hypercellular Ph1-positive ALL diagnosed in December 2003. He was treated by hyper C-VAD and imatinib. He reached complete cytological and chromosomal remission in March 2004, but within 6 weeks, Ph1-positive cells had reappeared and the molecular quantification of the b2a3 transcript was very high. Mab Campath was introduced and imatinib pursued. After six infusions of alemtuzumab, in May 2004, we observed a disappearance of Ph1-positive cells in the marrow and a profound decrease in b2a3 quantification. Unfortunately, we discontinued Mab Campath because of severe neurologic toxicity (peripheral neuropathy and myelitis) of unknown origin since we could not rule out its responsibility. It should be mentioned that in July 2004, Avivi et al 4 reported for the first time similar neurological complications following alemtuzumab-based reduced intensity allogeneic transplantation.
We share the remarks of P Piccaluga et al: Mab Campath, as shown with other monoclonal antibodies, should be used on low tumor load, and probably maintenance therapy is needed.
Although the data are scanty, we now reserve its use to ALL bearing the CD52 epitope and the CD52 antibody has been added to our immunophenotyping panel in order to select for the adequate patients. As indicated in our publication, we believe that the addition of cytokines, G-CSF in particular, may add to its efficacy by boosting ADCC.
In the absence of major other development for the treatment of adult ALL, which remains deceiving even with allogeneic stem cell transplantation, 5 we agree with the Bologna team that alemtuzumab at present time may be one of the best options to investigate along the lines described here and post transplantation. Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells [1] [2] [3] Among other obstacles, researchers using these techniques have to deal with the extraordinary instability of RNA ex vivo, which may result in marked differences of gene expression profiles. 4 In acute leukemias, peripheral blood is frequently used as a source of malignant cells. In daily practice, the percentage of blast cells is increased by the density gradient centrifugation (DGC) followed by immediate RNA stabilization with various RNA stabilizing agents, thereby ensuring stable gene expression results. However, the time passing by between the collection of blood specimens and DGC remains the critical step as RNA degrades gradually during that period.
The PAXgene blood RNA system (PreAnalytix, Hombrechtikon, Switzerland) is a bedside RNA stabilization system consisting of PAXgene blood RNA tubes and an RNA extraction kit. RNA is protected from the moment of blood specimen acquisition since the blood collection tube already contains the RNA stabilizing agent. It has been proven to preserve RNA quality and stable gene expressions when tested after 0, 1, 3 and 7 days of storage at ambient temperature. In contrast, these results could not be obtained with blood specimens that were collected and stored in conventional tubes (ie, with EDTA or heparine as anticoagulant) for the same time after which they were subjected to DGC with subsequent RNA extraction. 5, 6 However, when PAXgene tubes are used, DGC cannot be performed any more. Thus, expression analysis of a gene of interest is always performed from whole blood RNA and not exclusively from pure blastic RNA. We therefore wanted to evaluate whether these RNA bedside stabilizing kit systems were an appropriate tool for expression analysis in acute leukemias.
We investigated the expression of the C-RAF proto-oncogene, which is known to show a higher expression in granulocytes than in blasts, 7 in peripheral blood specimens from three patients with AML. The samples were characterized by a different percentage of blast cells (98, 70 and 20%, respectively) as measured by MayGruenwald Giemsa staining and flow cytometry. Blood was collected in both the PAXgene system and in lithium-heparin tubes, the latter being immediately subjected to DGC (Axis-Shield, Oslo, Norway) and subsequent RNA stabilization of blasts and granulocytes using Buffer RLT (Quiagen, Hilden, Germany). Total RNA was extracted from cells of the PAXgene tubes as well as separated blast cells and granulocytes and subjected to C-RAF expression analysis by RQ-PCR using the TaqMan methodology on an ABI PRISM 7000 sequence detection system (Applied Biosystems, Fosters City, CA, USA). We used the comparative DDC T method, where the C-RAF expression is first normalized to a control gene (c-ABL) and then compared to a calibrator. For each patient sample, the purified blast cells were chosen as calibrator, giving each of them a value of 1. Expression of the corresponding granulocytes and cells from the PAXgene system was displayed as the calibrator's x-fold expression. Primer and probe sequences are available upon request. C-RAF gene expression did not differ between cells from the PAXgene system and pure blast cells in the sample showing 98% leukemic cells. However, C-RAF expression of PAXgene system cells was already increased two-fold in the patient with 70% and more than three-fold in the patient with 20% blast cells as compared to the pure blastic fraction (Figure 1a) . To prove that this increased C-RAF expression is really due to contaminating granulocytes, we performed a serial dilution experiment. RNA isolated from a pure blast cell preparation as well as granulocytic RNA of the same patients were diluted to a final concentration of 200 ng/ml, diluted to the following ratios: 100-0; 80-20; 60-40; 40-60; 20-80; 0-100% and again subjected to expression analysis. Expression results were already different in the sample with 80% blastic RNA and continuously rose until they reached the normal granulocytic expression level when analyzing pure granulocytic RNA (Figure 1b) .
Bedside RNA stabilizing kit systems, such as PAXgene, have enriched the field of gene expression analysis. However, in acute leukemias the percentage of blast cells has to be taken into account as blastic RNA cannot be separated from contaminating non-neoplastic RNA with these systems. Our experiments clearly demonstrate that contamination with more than 10-20% nonblastic peripheral blood cells can lead to artificial gene expression results. Researchers should be aware of that and decide -based on the blast cell count of an individual patientwhether to use bedside RNA stabilizing kit systems or conventional preparation methods as Ficoll DGC. (a) Different C-RAF expression in the three patients (p1-3) in granulocytes, myeloblasts and RNA isolated from the PAXgene blood RNA system. Blast cell percentage was 98% in p1, 70% in p2 and 20% in p3. (b) Serial dilution experiment: pure blast cell RNA of p2 and p3 was serially diluted with granulocytic RNA of the same patients and subjected to expression analysis.
